Risk of cancer in Turkish patients after treatment with TNF antagonists

dc.contributor.authorPay, Salih
dc.contributor.authorÖztürk, M. Arif
dc.contributor.authorCan, Gerçek
dc.contributor.authorCefle, Ayşe
dc.contributor.authorÇobankara, Veli
dc.contributor.authorErer, Burak
dc.contributor.authorGögüş, Feride
dc.contributor.authorHatemi, Gülen
dc.contributor.authorİnanç, Nevsun
dc.contributor.authorKaraaslan, Yaşar
dc.contributor.authorKaradag, Ömer
dc.contributor.authorKrakoç, Yüksel
dc.contributor.authorKasapoğlu Günal, Esen
dc.contributor.authorKaşifoglu, Timuçin
dc.contributor.authorKeser, Gökhan
dc.contributor.authorKoca, Serdar
dc.contributor.authorÖktem, Selda
dc.contributor.authorÖzer, Hüseyin T. E.
dc.contributor.authorSayarlıoğlu, Mehmet
dc.contributor.authorSoy, Mehmet
dc.contributor.authorŞentürk, Taşkın
dc.contributor.authorTemel, Musa
dc.contributor.authorTerzioglu, Ender
dc.contributor.authorTiryaki, Olcay
dc.contributor.authorTürk, Tufan
dc.contributor.authorYücel, Eftal
dc.date.accessioned2024-07-12T21:00:23Z
dc.date.available2024-07-12T21:00:23Z
dc.date.issued2008en_US
dc.departmentFakülteler, Tıp Fakültesien_US
dc.description.abstracten_US
dc.identifier.doi10.1093/rheumatology/ken026
dc.identifier.endpage549en_US
dc.identifier.issn1462-0324
dc.identifier.issue4en_US
dc.identifier.pmid18296720en_US
dc.identifier.scopus2-s2.0-43049166010en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage548en_US
dc.identifier.urihttps://dx.doi.org/10.1093/rheumatology/ken026
dc.identifier.urihttps://hdl.handle.net/20.500.12415/3362
dc.identifier.volume47en_US
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherOxford University Pressen_US
dc.relation.ispartofRheumatologyen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKY08953
dc.titleRisk of cancer in Turkish patients after treatment with TNF antagonistsen_US
dc.typeLetter
dspace.entity.typePublication

Dosyalar